PARP14 and plasma cell myeloma: PARP14 was shown to be a newly produced drug target for carcinomas (such as diffuse large B-cell lymphoma, multiple myeloma, prostate carcinoma, and hepatocellular carcinoma) and allergic inflammation (Qin et al., 2019).